ArticleCancer research2017
Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Cancer letters · 2026Review
- CHK1 and CHK2 as Context-Dependent Rheostats of Genotoxic Stress: Implications for Cell Fate and Tumor Immunity.International journal of biological sciences · 2026Review
- Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance.Molecular oncology · 2025Article
- A novel risk model consisting of nine platelet-related gene signatures for predicting prognosis, immune features and drug sensitivity in glioma.Hereditas · 2024Article
- lncRNA CYTOR promotes lung adenocarcinoma gemcitabine resistance and epithelial-mesenchymal transition by sponging miR-125a-5p and upregulating ANLN and RRM2.Acta biochimica et biophysica Sinica · 2024Article
- The role of STK11/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression.Frontiers in cell and developmental biology · 2024Review
- SIRT3-dependent mitochondrial redox homeostasis mitigates CHK1 inhibition combined with gemcitabine treatment induced cardiotoxicity in hiPSC-CMs and mice.Archives of toxicology · 2023Article
- Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer.Scientific reports · 2022Article
- RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.Science advances · 2022Article
- LKB1: Can We Target an Hidden Target? Focus on NSCLC.Frontiers in oncology · 2022Review
- STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications.European journal of cancer (Oxford, England : 1990) · 2021Article
- The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.Oncogene · 2021Article
- A Tiered Female Ovarian Toxicity Screening Identifies Toxic Effects of Checkpoint Kinase 1 Inhibitors on Murine Growing Follicles.Toxicological sciences : an official journal of the Society of Toxicology · 2020Article
- Ribonucleotide Reductases: Structure, Chemistry, and Metabolism Suggest New Therapeutic Targets.Annual review of biochemistry · 2020Review
- Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivityAging · 2020Article
- Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation.Journal of hematology & oncology · 2020Article
- Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.Nature reviews. Cancer · 2019Review
- LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer.International journal of molecular sciences · 2019Review
- Establishment of TP53-knockout canine cells using optimized CRIPSR/Cas9 vector system for canine cancer research.BMC biotechnology · 2019Article
- Long non-coding RNA LINC00485 acts as a microRNA-195 sponge to regulate the chemotherapy sensitivity of lung adenocarcinoma cells to cisplatin by regulating CHEK1.Cancer cell international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Yan LiuDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Yuyang LiShandong Provincial Hospital affiliated to Shandong University, Jinan, China.
Xiaoen WangDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Feiyang LiuHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
Peng GaoDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Max M QuinnDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Fei LiDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Ashley A MerlinoDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Cyril BenesCenter for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.
Qingsong LiuHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
Nathanael S GrayDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts.
Kwok-Kin WongLaura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center New York, New York. kwok-kin.wong@nyumc.org.
Dana-Farber Cancer Institute · USHigh Magnetic Field Laboratory · CNCenter for Cancer Research · USNYU Langone Health · USShandong Provincial Hospital · CN
Funding
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MTherapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5MTargeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung CancerU01CA213333 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GRAY, NATHANAEL SCHIANDER, WONG, KWOK KIN · 2017 to 2021
$3.3MTherapeutic approaches for LKB1-deficient non-small cell lung cancerR01CA205150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., WONG, KWOK KIN · 2016 to 2020
$3.0MIn vivo analysis of EGFR mutant driven lung cancers responses to radiation therapR01CA122794 · NCI · DANA-FARBER CANCER INST · PI WONG, KWOK KIN · 2006 to 2015
$2.8MIn vivo murine models of metastasis for therapeutic testingR01CA163896 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHARPLESS, NORMAN E, WONG, KWOK KIN · 2012 to 2016
$2.0MCredentialing Mouse Models for Immune System Therapy ResearchR01CA195740 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, WONG, KWOK KIN · 2015 to 2017
$1.8MNCI NIH HHS R01 CA122794NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA163896NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA195740NCI NIH HHS R01 CA205150NCI NIH HHS U01 CA213333
Abstract
Cells lacking the tumor suppressor gene
Indexed as
Drug SynergismAdenocarcinomaAMP-Activated Protein Kinase KinasesAnimalsAntimetabolites, AntineoplasticApoptosisBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell ProliferationCheckpoint Kinase 1DeoxycytidineDrug Therapy, CombinationFemaleGemcitabineHumansLung Neoplasms3-(carbamoylamino)-5-(3-fluorophenyl)-N-(3-piperidyl)thiophene-2-carboxamideAMP-Activated Protein Kinase KinasesAntimetabolites, AntineoplasticBiomarkers, TumorCheckpoint Kinase 1CHEK1 protein, humanDeoxycytidineGemcitabineKRAS protein, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)STK11 protein, humanThiophenesTumor Suppressor Protein p53Urea
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.